OncoSynergy
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
329 Oyster Point Blvd Fl 3, South San Fr...Phone Number
(415) 666-2391Website
www.oncosynergy.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About OncoSynergy
OncoSynergy is a clinical-stage immuno-oncology company based in Stamford, CT, focused on developing next-generation immunotherapies for patients with recurrent glioblastoma and other rare and resistant cancers. Their primary investigational drug, OS2966, is designed to be delivered directly to the brain using convection-enhanced delivery to overcome the blood-brain barrier. The company targets various malignancies, including ovarian and pancreatic cancers, as well as hematological malignancies like drug-resistant acute lymphoblastic leukemia. OncoSynergy aims to provide patient-focused therapies that improve treatment outcomes for individuals facing challenging cancer diagnoses.Explore more
OncoSynergy Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is OncoSynergy your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if OncoSynergy had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if OncoSynergy has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once OncoSynergy has new funding data
OncoSynergy, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when OncoSynergy launches new products
Check out if OncoSynergy is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at OncoSynergy
Earning: See what the market has to say on OncoSynergy recently announced quarterly report
Recommended Actions
Find VP level buyers at OncoSynergy
Find 2 more new buyers
Compare Similar Companies to OncoSynergy
Compare insights from companies similar to OncoSynergy, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$630.2M
1K - 5K
Public
$300M
2000
JC
Johnny ChengExecutive Director, Chief Financial Officer & Acting CEO
Company Profile Activity
Activity Insights
OncoSynergy is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
OncoSynergy is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about OncoSynergy.
OncoSynergy financials insights
Gather financial insights about OncoSynergy, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$118K
2026
Private Equity
$6.6M
OncoSynergy Tech Stack
A closer look at the technologies used by OncoSynergy
See more technologies
OncoSynergy News & Media
OncoSynergy Receives $300,000 STTR Grant to Develop Novel Oncolytic Virus
Funding expands immunotherapy pipeline (PRWeb January 14, 2020) Read the full story at https://www.prweb.com/releases/oncosynergy_receives_300_000_sttr_grant_to_develop_novel_oncolytic_virus/prweb16820569.htmOncoSynergy Announces FDA Acceptance of IND Application for Phase I Trial of OS2966 in Patients with Recurrent Glioblastoma
Enrollment in OS2966 First-in-Human Phase I Clinical Trial in 2019 (PRWeb April 02, 2019) Read the full story at https://www.prweb.com/releases/oncosynergy_announces_fda_acceptance_of_ind_application_for_phase_i_trial_of_os2966_in_patients_with_recurrent_glioblastoma/prweb16213778.htmOncoSynergy Announces Submission of IND Application for OS2966 in the...
OncoSynergy announced that it has submitted an FDA application for a first-in-human trial of its Orphan Drug designated experimental therapeutic OS2966 for malignant brain cancer. (PRWeb February 26, 2019) Read the full story at https://www.prweb.com/releases/oncosynergy_announces_submission_of_ind_application_for_os2966_in_the_treatment_of_glioblastoma/prweb16125039.htmOncoSynergy Raises Series A Funding Round
OncoSynergy, a South San Francisco, CA-based oncology therapeutics spinout from UCSF, closed a Series A equity funding round. The round was led by Connecticut Innovations (CI) with participation from current shareholders NLabs, Inc., and Korea Information & Communication Co., Ltd. The company intends to use the funds to accelerate their lead program, OS2966, to the […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding OncoSynergy
Sign Up For FreeTo access detailed company insights
OncoSynergy is a clinical-stage immuno-oncology company based in Stamford, CT, focused on developing next-generation immunotherapies for patients with recurrent glioblastoma and other rare and resistant cancers. Their primary investigational drug, OS2966, is designed to be delivered directly to the brain using convection-enhanced delivery to overco... Read More
